CTOs on the Move


 
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.gen9bio.com
  • 840 Memorial Drive Fifth Floor
    Cambridge, MA USA 02139
  • Phone: 617.250.8433

Executives

Name Title Contact Details

Similar Companies

Response Genetics

Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palatin Technologies

Palatin Technologies is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ribometrix

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.

Alternatives Technologies Pharma

Alternatives Technologies Pharma Inc. is a Chicoutimi, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alltrna

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna`s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.